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n 2003, the Seventh Report of the Joint
National Committee on Prevention,
Detection, Evaluation, and Treatment
of High Blood Pressure (JNC VII) pub-
lished its ultimate guidelines for hyper-
tension prevention and management (1).
One of the key messages was the deﬁni-
tion of a new category of blood pressure
(BP) levels, i.e., prehypertension, that in-
cluded individuals with a systolic BP of
120–139 mmHg or a diastolic BP of
80–89 mmHg. Patients with prehyper-
tension were considered at increased risk
for progression to hypertension and indi-
viduals in the 130/80 to 139/89 mmHg
range were at twice the risk of developing
hypertension than subjects with lower
values(2).Inthesameyear,theEuropean
Society of Hypertension and the Euro-
pean Society of Cardiology (ESH-ESC)
published their guidelines for the man-
agement of arterial hypertension and, for
the same range of BP, two different cate-
goriesofBPweredeﬁned:normalBP(sys-
tolic BP of 120–129 mmHg, or diastolic
BPof80–84mmHg)andhigh-normalBP
(systolic BP of 130–139 mmHg, or dia-
stolic BP of 85–89 mmHg) (3).
In 2007, the ESH-ESC committee de-
cided against using the term “prehyper-
tension” for several reasons (4). First,
evenintheFraminghamstudy,theriskof
developing hypertension was deﬁnitely
higher in subjects with high-normal BP
thaninpatientswithnormalBP(2,5),and
therefore there is little reason to combine
the twogroups.Second,giventheominous
signiﬁcance of the word “hypertension” for
the layman, the term “prehypertension”
may, in many subjects, create anxiety and
a request for unnecessary medical visits
and examinations. Finally, although life-
style changes recommended by the 2003
JNCVIIguidelinesforallprehypertensive
individuals may be a valuable population
strategy (1), in practice, this category is a
highly differentiated one, with the ex-
tremesconsistingofsubjectswithnoneed
of any intervention (e.g., an elderly indi-
vidual with a BP of 120/80 mmHg), as
well as of those with a very high or high
cardiovascular risk proﬁle (e.g., after
stroke or with diabetes), in whom drug
treatment is required.
Because the evidence of BP-lowering
beneﬁts in patients with high-normal BP
were limited to subjects with stroke (6),
coronary artery disease (7), and diabetes
(8), antihypertensive treatment within
this BP range was only recommended for
patients at high risk (3). In 2007, the up-
datedESH-ESCguidelinesrecognizedpa-
tients presenting with diabetes or
metabolicsyndromeashighorvery-high-
risk patients (4). The present review will
focus on the beneﬁts of antihypertensive
therapy in patients with diabetes, or met-
abolic syndrome and high-normal BP.
HIGH-NORMAL BP AND
CARDIOVASCULAR
RISK— Several epidemiologic studies
have demonstrated that systolic and dia-
stolic BP values have a strong continuous
graded and etiologically signiﬁcant posi-
tive association with cardiovascular dis-
ease (CVD) outcomes (9). Although
subjectswithhigh-normalBParelikelyto
have an elevated risk of CVD (given the
continuum of risk), there was a paucity of
information regarding the absolute and
relative risks of CVD in these individuals.
Vasan et al. (5) published a prospective
examination of the risk of CVD in men
and women with high-normal BP, in-
tended to investigate the association be-
tween BP category at baseline, and the
incidence of CVD on follow-up among
6,859 participants in the Framingham
Heart Study. During a mean follow-up of
11.1 years, 397 study subjects had a ﬁrst
cardiovascularevent,including72deaths
from CVD, 190 recognized myocardial
infarctions, 85 strokes, and 50 cases of
congestive heart failure. Cardiovascular
event rates increased in a stepwise man-
ner across the three BP categories (opti-
mal, normal, and high-normal BP) (5)
(Fig. 1). Compared with optimal BP,
high-normalBPwasassociatedwitharisk
factoradjustedhazardratio(HR)forCVD
of 2.5 (95% CI 1.6–4.1) among women
and 1.6 (1.1–2.2) among men (5).
Moreover, among subjects with no
previous vascular disease, the usual BP
values are positively related to the risks of
death from vascular disease, not only
among hypertensive patients or subjects
with high-normal BP, but also among
those who would usually be considered
normotensive (at least down to usual BP
levels of 115/75 mmHg) (10). Given the
continuous relationship observed be-
tween BP and risk of death from vascular
disease, the absolute beneﬁts of a lower
BP level are likely to be greatest for those
at maximum absolute risk of vascular dis-
ease (10). At ages 40–69 years, each dif-
ference of 20 mmHg usual systolic BP (or
approximately equivalent to 10 mmHg
usualdiastolicBP)isassociatedwithmore
than a twofold difference in stroke death
rate and with twofold differences in the
death rates from ischemic heart disease
and other vascular causes. All these pro-
portionaldifferencesinvascularmortality
are about half as extreme at ages 80–89
years than at ages 40–49 years, but the
annual absolute differences in risk are
greater in old age (10).
AlthoughtherelationshipbetweenBP
categories and cardiovascular risk is
ﬁrmly established, there is scarce evi-
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lar events in subjects with progressive BP
increase and in whom new onset of hy-
pertension occurs. This question is im-
portant, because people with BP levels in
the normal and high-normal range have a
substantial risk of developing hyperten-
sion over a short-term period. In the Fra-
minghamcohort,aftera4-yearfollow-up,
the hypertension incidence rates pro-
gressed according to baseline BP category
and age: among younger people (age
35–64 years) with optimum, normal, or
high-normal baseline BP, the 4-year rates
of hypertension were 5.3, 17.6, and
37.3%, respectively; among older people
(age 65–94 years), these rates were 16.0,
25.5, and 49.5%, respectively (2). Data
Figure 1—Cumulative incidence of cardiovascular events in women (A) and men (B) according to BP category. From Vasan et al. (5).
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shown that 30.1% of women without
baseline hypertension progressed to hy-
pertension (11). The age-adjusted event
rate for the primary end point was 1.6/
1,000 person-years among women with
normal BP, 2.9/1,000 person-years
among those with high-normal BP, and
4.3/1,000 person-years among those
with baseline hypertension. Compared
with women with high-normal BP,
those with normal BP had a lower risk of
a major cardiovascular event (adjusted
HR 0.61, 95% CI 0.48–0.76) and of in-
cident hypertension (0.42, 0.40–0.44).
The HR for a major cardiovascular event
inwomenwithbaselinehypertensionwas
1.30 (1.08–1.57). Women who pro-
gressed to hypertension during the ﬁrst
48 months of the study had a higher car-
diovascularriskthanthosewhoremained
normotensive (adjusted HR 0.64, 0.50–
0.81). Women with high-normal BP at
baseline who progressed to hypertension
had similar outcome rates to those with
baseline hypertension (adjusted HR 1.17,
0.88–1.55) (11). Recent population data
conﬁrm that a substantial proportion of
CVD is attributable to high BP. This bur-
denappliestodifferenteconomicregions,
age-groups, and BP levels and is not lim-
ited to subjects with hypertension, in
view of the large number of people with
high BP, but who are not classiﬁed as hy-
pertensive (12). Worldwide, 7.6 million
premature deaths (13.5% of the global
total) and 92 million disability-adjusted
life-years (6.0% of the global total) were
attributed to high BP. About 50% of this
afﬂictionoccurredinindividualswithhy-
pertension, but the remainder was in in-
dividuals with lesser degrees of high BP
(12).
BP VALUES AND
CONCOMITANT RISK
FACTORS— Only a small fraction of
the hypertensive population has an eleva-
tion of BP alone, with the great majority
exhibiting additional cardiovascular risk
factors, with a relationship between the
severity of the BP elevation and that of
alterations in glucose and lipid metabo-
lism. Furthermore, when concomitantly
present, BP and metabolic risk factors po-
tentiate each other, leading to a total car-
diovascular risk that is greater than the
sum of its individual components (4). In
fact, after the algorithm of ESH-ESC to
stratify cardiovascular risk, subjects with
high-normal BP presenting three addi-
tional cardiovascular risk factors, meta-
bolic syndrome, or diabetes are
considered as high-risk patients (Fig. 2)
(4). The Strong Heart Study demon-
strated that prehypertension was more
prevalent in diabetic than nondiabetic
participants (59.4 versus 48.2%), and pa-
tients presenting with both diabetes and
prehypertension had the highest cumula-
tive incidence of CVD during follow-up
(Fig. 3) (13). In nondiabetic participants,
prehypertensionincreasedcardiovascular
events 1.8-fold compared with their nor-
motensive counterparts. Diabetes alone
increased the risk of CVD by 2.9-fold
compared with normotensive nondia-
betic participants. Diabetes plus prehy-
pertensionincreasedtheCVDriskby3.7-
fold. When the prehypertensive category
was stratiﬁed into those with normal or
high-normal BP, HRs for those in the
highergroupweregreater,buttherewasa
signiﬁcant risk even in those in the lower
group. The coexistence of impaired glu-
cose tolerance, or impaired fasting glu-
cose and prehypertension, also increased
CVD risk signiﬁcantly compared with
normotensive participants with normal
glucose tolerance (Fig. 4) (13).
HIGH-NORMAL BP AND
ANTIHYPERTENSIVE
THERAPY— The recommendation to
initiate treatment in diabetic patients
when BP is still in the high-normal range,
and to reduce BP to 130/80 mmHg, is
supported by European Guidelines (4).
The same can be considered for patients
with three or more cardiovascular risk
factors, presence of target organ damage,
or metabolic syndrome. Considering that
thepresenceofthemetabolicsyndromeis
relatedtoanincreasedcardiovascularrisk
(14,15), it is possible that hypertensive
patients with metabolic syndrome would
obtainanadditionalbeneﬁtoncardiovas-
cular prognosis with the achievement of a
Figure 2—Stratiﬁcation of cardiovascular (CV) risk in four categories. From Mancia et al. (4).
DBP, diastolic blood pressure; HT, hypertension; MS, metabolic syndrome; OD, subclinical organ
damage; SBP, systolic blood pressure.
Figure 3—Cumulative CVD incidence during 12 years of follow-up by prehypertension and
diabetes status in the Strong Heart Study cohort. From Zhang et al. (13).
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diabetic patients. The clinical evidence
that inﬂuenced our attitude toward treat-
ing a patient was fundamentally obtained
from studies aimed at identifying signiﬁ-
cantdifferencesontheﬁnalconsequences
of cardiovascular and renal diseases
(nonfatalevents,chronicorterminalre-
nal insufﬁciency, and cardiovascular
mortality). Nevertheless, cardiovascular
and renal diseases have developed pro-
gressively throughout many years. This
process is accompanied by a parallel pro-
gressionofatherosclerosisthatﬁnallywill
be converted into atherothrombotic
events, which are the fundamental cause
of fatal and nonfatal cardiovascular and
renal events. Therefore, early detection of
an elevated cardiovascular risk through
the clustering of cardiovascular risk fac-
tors and/or the presence of target organ
damageshouldbefollowedbypromptin-
tervention. In fact, the Losartan Interven-
tionforEndpointReduction(LIFE)study
clearly demonstrated that regression of
electrocardiographic left ventricular hy-
pertrophy with antihypertensive treat-
ment improved prognosis, independent
of BP (16). Moreover, the multicenter
double-blind randomized Bergamo
Nephrologic Diabetes Complications
Trial (BENEDICT) was designed to assess
whether ACE inhibitors and nondihydro-
pyridine calcium-channel blockers, alone
or in combination, prevent microalbu-
minuria in subjects with hypertension,
type 2 diabetes, and normal urinary albu-
min excretion (17). The primary end
point was the development of persistent
microalbuminuria (overnight albumin
excretion, 20 g/min at two consecu-
tive visits). This end point was reached in
5.7% of the subjects who received tran-
dolapril plus verapamil, 6.0% trandola-
pril, 11.9% verapamil, and 10.0% of
control subjects who received placebo. In
conclusion, in subjects with type 2 diabe-
tesandarterialhypertension,normoalbu-
minuria, and normal renal function, ACE
inhibitor therapy with trandolapril plus
verapamil, or trandolapril alone, pre-
vented the onset of microalbuminuria. In
our experience, the implementation of
guidelines for management of essential
hypertension and cardiovascular risk fac-
tors facilitates the achievement of similar
BP and LDL cholesterol goals, in patients
with and without metabolic syndrome.
However, it seems that global cardiovas-
cular risk would remain higher in treated
hypertensive subjects presenting with
metabolic syndrome, as suggested by a
threefold higher incidence of new-onset
diabetes and double prevalence of posi-
tive microalbuminuria (18).
High-normal BP and the initial stage
of isolated systolic hypertension represent
two situations in which doctors frequently
are reluctant to start pharmacologic ther-
apy, albeit according to guidelines, this
could clearly be beneﬁcial (19). In dia-
betic patients with high-normal BP, the
American Diabetes Association recom-
mends lifestyle therapy alone for a maxi-
mum of 3 months, and then, if targets are
not achieved, patients should be treated
with the addition of pharmacological
agents (20). Updated ESH-ESC guide-
lines recommend lifestyle changes plus
drug treatment at the outset (4).
Subjects with a high cardiovascular
risk due to factors other than diabetes,
but a BP still in the high-normal range,
should be advised to implement intense
lifestyle measures (including smoking
cessation), and BP should be closely
monitoredbecauseoftherelativelyhigh
chance these individuals have of devel-
oping hypertension, which would then
require drug treatment. However, phy-
sicians and patients may sometimes
consider antihypertensive drugs, par-
ticularlythosemoreeffectiveinprotect-
ing against organ damage, new-onset
hypertension, and new-onset diabetes
(4). In fact, pharmacologic treatment of
prehypertension may prevent or post-
pone the development of hypertension.
The TROPHY (Trial of Preventing Hy-
pertension) trial showed a signiﬁcant
reduction in incident hypertension in
participants with prehypertension who
had received candesartan. The relative
proportionofparticipantswhowerehyper-
tension-free was 26.5% greater in the can-
desartan group (21). Chronic blockade of
the renin-angiotensin system appears to
be particularly effective in preventing re-
nal and cardiovascular events in patients
with type 2 diabetes. Patients with hyper-
tension are at increased cardiovascular
risk, which is ampliﬁed by the coexist-
ence of type 2 diabetes. Blockade of the
renin-angiotensin system lowers BP in
both hypertensive and diabetic individu-
als, suggesting the underlying contribu-
tion of angiotensin II to the pathogenesis
of these conditions and, possibly, of their
renal and cardiovascular complications.
This is compatible with the fact that an-
giotensin II has been recognized as play-
ingadeleteriousroleearlyinthecourseof
the atherosclerotic process (22). It ap-
pears, therefore, highly desirable to block
the renin-angiotensin system in all pa-
tientswithhypertensionand/ortype2di-
abetes. Ideally, this should be done early
during the course of the disease, since
blockers of the renin-angiotensin system
are effective in reducing oxidative stress,
plasma concentrations of inﬂammatory
mediators, and plasminogen activator in-
hibitor 1, as well as in improving endo-
thelial function, i.e., abnormalities that
may be encountered before the existence
ofstructuralvasculardamage(23).Block-
ers of the renin-angiotensin system have
an additional advantage compared with
other classes of antihypertensive agents:
they improve insulin sensitivity and may
protect against the progressive impair-
ment of -cell secretory function ob-
served in patients with type 2 diabetes
(24).Thisbeneﬁcialeffectmayberelatedin
parttothepreventionoftheangiotensinII–
mediated increase in oxidative stress. In
Figure 4—Hazard ratios for incident CVD associated with prehypertension and glucose meta-
bolic abnormalities on a logarithmic scale. From Zhang et al. (13). DM, diabetes; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
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that diuretic therapy, particularly when
combined with a -blocker, diminishes
glucosetoleranceandincreasestheriskof
new-onset diabetes, and by contrast,
treatment with antihypertensive drugs
such as ACE inhibitors, or angiotensin-
receptor blockers, and to a lesser extent
calcium antagonists, seems to decrease
this risk (25). It appears increasingly jus-
tiﬁed that the use of these drugs in pa-
tientswithmetabolicsyndromeshouldbe
extended, since inhibition of the renin-
angiotensin system not only lowers BP,
but also reduces the incidence of new-
onset type 2 diabetes (25).
CONCLUSIONS — Epidemiologic
studies have demonstrated that systolic
and diastolic BP values have a strong,
continuous, graded, and etiologically
signiﬁcant positive association with
CVD outcomes. This is especially rele-
vant among subjects with high-normal
BP, considering that most will or will
not receive a more aggressive pharma-
cologictherapytocontrolBPvalues,de-
pending on the presence or absence of
concomitant comorbidities (diabetes,
clusteringofcardiovascularriskfactors,
target organ damage, and metabolic
syndrome). It is well established that
the use of pharmacologic therapy from
the early stages of BP in these patients
will greatly facilitate the achievement of
adequate BP control, which will con-
tribute to the prevention of cardiovas-
cular complications.
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